Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LPAD As An Afterthought? Insmed’s Arikayce Reaches US Market Thanks To Limited Population Pathway

Executive Summary

Amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex lung disease is first antimicrobial approved under 21st Century Cures Act pathway; LPAD designation request appears to have occurred after an advisory committee recommended approval for more limited population than requested by Insmed.


Advertisement

Related Content

A Call To Action On Antibiotic Development
LPAD Approval Pathway Is Not Saving Antimicrobial Development
Non-Traditional Antimicrobials Can Follow Regulatory Path Laid By Small Molecule Antibiotics, US FDA Says
Insmed's Amikacin Has US FDA Questioning Microbiological Endpoint Vs. Clinical Benefit
Insmed’s Amikacin Gains US FDA Panel Nod For Refractory Lung Disease
Insmed’s Amikacin Faces US FDA Questions On Surrogate Endpoint, Target Population
Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out
Plazomicin's BSI Indication Gets 'No' From Advisory Panel, But US FDA Still Might Approve Under LPAD Pathway
Antibiotic Development: Limited Population Pathway In US Removes Barrier

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel